第7章 中国市場におけるウロキナーゼの主要製薬会社

第8章 中国におけるウロキナーゼの市場見通し

市場規模の予測

競合情勢の予測

目次

Product Code: 1508298

As a serine protease, urokinase is isolated from human urine or cultivated in kidneys. And it consists of LMW-tcu-PA and HMW-tcu-PA.

Activation of urokinase triggers a proteolysis cascade that participates in thrombolysis degradation. Urokinase not only immediately removes clot but also enhances the activity of ADP enzyme so as to inhibit the platelet aggregation and prevent thrombolysis. Activity of plasmin is improved when urokinase is given in the form of intravenous drip and falls back to normal level several hours later. As a traditional thrombolytic drug, urokinase is widely used in treating such thrombotic diseases as acute myocardial infarction, cerebral thrombosis, pulmonary vein thrombus and deep vein thrombosis.

With aging population and unreasonable eating habit, the incidence of thrombotic disease has gone up, which promotes the demand for urokinase. According to CRI's market survey, the annual sales value of urokinase rose from CNY 18.20 million in 2010 to CNY 28.95 million in 2014 with CAGR during this period reaching 12.30%. NDPHARM had the largest market share of about 48.5% for sales value in 2014.

The market size of urokinase is expected to keep growing in the next few years in China.

Readers can get at least the following information through this report:

market size of urokinase in China

competitive landscape of urokinase market in China

price of urokinase made by different enterprises in China

market outlook of urokinase in China

The author suggests the following groups of people purchase this report: